We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer (THOR)

This study has been withdrawn prior to enrollment.
(Due to missing patient recruitment, the financial support was stopped.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01985893
First Posted: November 15, 2013
Last Update Posted: January 14, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
OnkoDataMed GmbH
Information provided by (Responsible Party):
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)